BiomX Inc.

BiomX Inc. (Nasdaq: PHGE) is a clinical-stage biopharmaceutical company focused on developing phage-based therapies targeting bacteria associated with chronic diseases, including skin conditions and respiratory infections. The company completed its initial public offering in 2019 through a merger with Chardan Healthcare Acquisitions Corp., a blank-check vehicle sponsored by Chardan Capital Markets. Operating in the biotechnology and microbiome-therapeutics sector, BiomX filed an 8-K current report with the SEC on September 1, 2026, under accession number 0001213900-26-096273. For comprehensive filing history, clinical pipeline status, and real-time SPAC transaction data on BiomX and thousands of other deals, sign up for full access at SpacDesk.